Form 8-K - Current report:
SEC Accession No. 0001104659-25-038301
Filing Date
2025-04-24
Accepted
2025-04-24 06:45:16
Documents
17
Period of Report
2025-04-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2512885d1_8k.htm   iXBRL 8-K 39416
2 EXHIBIT 99.1 tm2512885d1_ex99-1.htm EX-99.1 324378
3 EXHIBIT 99.2 tm2512885d1_ex99-2.htm EX-99.2 320946
8 GRAPHIC tm2512885d1_ex99-1img001.jpg GRAPHIC 14279
  Complete submission text file 0001104659-25-038301.txt   1002122

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrk-20250424.xsd EX-101.SCH 4655
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20250424_def.xml EX-101.DEF 29174
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20250424_lab.xml EX-101.LAB 39688
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20250424_pre.xml EX-101.PRE 27658
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2512885d1_8k_htm.xml XML 11323
Mailing Address 126 EAST LINCOLN AVENUE P.O. BOX 2000 RAHWAY NJ 07065
Business Address 126 EAST LINCOLN AVENUE P.O. BOX 2000 RAHWAY NJ 07065 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 25863502
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)